Please ensure Javascript is enabled for purposes of website accessibility
Accueil > Products > Kits d'Essai > Kits d'Essai ADA
Lintuzumab ELISA Kit
Lintuzumab ELISA Kit
Prix(USD) :
Spécification :
  • 96T
Nombre :
Contactez-nous
  • Aperçu

  • Images

  • Reférences

  • Fiche technique

  • SDS

Aperçu
Numéro de catalogueDB185018
Description
Lintuzumab ELISA Kit (DB185018) — Quantitative sandwich ELISA for Lintuzumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml.
Highlights
  • ●Sandwich Format — High specificity, reliable quantification.
  • ●High Sensitivity — Optimized for low-abundance target detection.
  • ●Ready-to-Use — Complete kit with pre-coated plates included.
Type d'échantillonPlasma, Serum
Sensibilité0.156 μg/ml
Plage0.31-5 μg/mL
Numéro d'accès P20138
Applications ELISA
Méthode de détection Colorimetric
Type de test Quantitative
Retraitement 80-120%
Expédition 2-8 ℃
Stabilité et stockage The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Spécifications

Lintuzumab

Noms alternatifs225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, 166089-32-3
Contexte

Myeloid cell surface antigen CD33 (Lintuzumab) is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules.

1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343
2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212
3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323
4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872
5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109
6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905
7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955
8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798
Note For Research Use Only.
Images
  • Lintuzumab ELISA Kit

    Standard Curve

    Standard Curve of Lintuzumab ELISA Kit

Reférences
Fiche technique
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : [email protected]

Liste des distributeurs